However, similarly to other studies in European populations, no association were observed between the TGFBR2-875/A polymorphism and PC risk. In addition, it appears that this polymorphism may have no influence on the onset of PC but instead it can modulate its progression to an aggressive phenotype. In our control population the frequency of the TGFBR2-875G>A polymorphism tended to be similar to those observed in other Caucasian healthy populations like in Finland and Poland. However, the frequencies are also similar to those observed in studies performed in Republic of Korea and North of China. Additionally, we observed that the frequency of the TGFBR2-875GG genotype was lower than the one of the control group used in the study performed by Seijo and co-workers in an American population and higher than the reported results in the control group that included Cantonese healthy subjects from population in southern China. Survival of the PC patients and CR development are related to several variables that include the extent of the initial tumor, PSA levels, patients’ age, which are useful tools for therapeutic decisions. However, due to some predictive limitations, they do not exactly reflect the biologic behavior of PC, and many men can die from aggressive disease. Additional results showed that the definition of profiles that contains information regarding tumor characteristics associated with genetic information 
have a higher capacity to predict the risk for CR development. Therefore, we hypothesize that the definition of a predictive profile that contains the TGFBR2-875G>A polymorphism information could be useful as molecular marker for predicting the clinical response to ADT in patients with PC. However, future studies should replicate this predictive model in another PC study population submitted to ADT. In conclusion, the present study suggests that the functional polymorphism TGFBR2-875G>A does not modify the predisposition to PC in our population. However, this SNP has the capacity to change the TGFBR2 mRNA expression levels in PC patients submitted to ADT and influence the CRFI, with a lower time interval to CR in TGFBR2-875GG homozygous compared with TGFBR2-875AG/AA patients carriers. In the future, the identification of these genetic profiles may help to define new effective prognostic models for the follow up of patients submitted to ADT and identifying higher risk groups for an individualized chemoprevention strategy and target therapies. Cystic fibrosis is a common inherited disease among Caucasians, affecting approximately 1 in 3000 births. CF affects 30,000 children and young adults in the United States. The progression of CF lung disease is variable, even among individuals sharing the same mutation in the cystic fibrosis transmembrane regulator. Recent progress in animal models such as the cystic fibrosis pig have expanded the understanding of CF pathogenesis.